newsfilter
← Earnings
Earnings Releases·

ArriVent BioPharma — Third Quarter 2026 Earnings Summary

  • Net loss for the nine months ended September 30, 2026, was $133.5 million, a slight increase from $130.8 million in 2025, while cash and investments totaled $393.2 million, sufficient to fund operations through mid-2028.
  • Collaboration revenue reached $5.0 million for the nine-month period, compared to $0 in 2025, driven by new partnerships, though general and administrative expenses rose to $28.3 million from $17.5 million.
  • The Phase 3 FURVENT study failed to meet its primary endpoint of progression-free survival by blinded independent central review, prompting a detailed data review, while the pivotal Phase 3 ALPACCA study enrollment continues on track.
  • Management announced the appointment of Dr. Priti Patel as Chief Medical Officer and the retirement of co-founder Dr. Stuart Lutzker, with clinical data updates for firmonertinib and ARR-217 expected in 2027.
Company
ARRIVENT BIOPHARMA INC
Sector
Healthcare
Industry
Biotechnology